Aignostics
Founded Year
2018Stage
Series B | AliveTotal Raised
$53.94MLast Raised
$34M | 1 yr agoMosaic Score The Mosaic Score is an algorithm that measures the overall financial health and market potential of private companies.
+118 points in the past 30 days
About Aignostics
Aignostics specializes in AI-powered precision medicine, focusing on the biopharmaceutical industry. The company offers insights by analyzing complex biomedical data, including histopathology, omics, and clinical outcomes, to support drug development and improve patient outcomes. It serves the biopharma sector with solutions for target identification, translational research, trials, and companion diagnostics. It was founded in 2018 and is based in Berlin, Germany.
Loading...
Aignostics's Product Videos
ESPs containing Aignostics
The ESP matrix leverages data and analyst insight to identify and rank leading companies in a given technology landscape.
The digital pathology for general diagnostics market refers to the use of digital imaging technology and computational tools to analyze and interpret pathology specimens for diagnostic purposes. Instead of using traditional glass slides, digital pathology involves digitizing tissue samples and creating high-resolution images that can be viewed and analyzed on computer screens. These digital images…
Aignostics named as Highflier among 15 other companies, including Philips, Proscia, and Ibex.
Aignostics's Products & Differentiators
R&D
Identify and test novel biomarker / therapy combinations with pharma and biotech, as well as our academic partners.
Loading...
Research containing Aignostics
Get data-driven expert analysis from the CB Insights Intelligence Unit.
CB Insights Intelligence Analysts have mentioned Aignostics in 5 CB Insights research briefs, most recently on Aug 7, 2025.
Expert Collections containing Aignostics
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Aignostics is included in 6 Expert Collections, including Artificial Intelligence.
Artificial Intelligence
12,626 items
Companies developing artificial intelligence solutions, including cross-industry applications, industry-specific products, and AI infrastructure solutions.
Digital Health
11,438 items
The digital health collection includes vendors developing software, platforms, sensor & robotic hardware, health data infrastructure, and tech-enabled services in healthcare. The list excludes pureplay pharma/biopharma, sequencing instruments, gene editing, and assistive tech.
Oncology Tech
568 items
This collection includes companies applying technology to cancer care, diagnosis, and treatment. Examples include vendors offering cancer detection and diagnosis, oncology clinical decision support, real-world data, and AI oncology drug discovery.
Generative AI
2,807 items
Companies working on generative AI applications and infrastructure.
Digital Health 50
50 items
AI in drug discovery
524 items
Companies using AI to advance therapeutic discovery, categorized into: platforms (primary product is software) and discovery engines (primary product is therapeutics). Additional funnel descriptions reflect how companies are applying AI.
Aignostics Patents
Aignostics has filed 2 patents.
The 3 most popular patent topics include:
- machine learning
- anatomical pathology
- artificial neural networks
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
11/17/2023 | 9/10/2024 | Staining, Artificial neural networks, Histopathology, Machine learning, Anatomical pathology | Grant |
Application Date | 11/17/2023 |
|---|---|
Grant Date | 9/10/2024 |
Title | |
Related Topics | Staining, Artificial neural networks, Histopathology, Machine learning, Anatomical pathology |
Status | Grant |
Latest Aignostics News
Jul 30, 2025
by Gus Iversen , Editor in Chief | July 30, 2025 Rating saved Mayo Clinic has installed NVIDIA’s DGX SuperPOD infrastructure, featuring the new DGX B200 systems powered by the Blackwell architecture, to accelerate the development of foundation models for clinical use. The Rochester, Minnesota-based health system is integrating the high-performance computing platform to support applications in digital pathology, precision medicine and drug discovery. According to Mayo Clinic, the system is already helping reduce the time required for AI model training—such as pathology slide analysis—from four weeks to one. The deployment is part of Mayo’s broader digital transformation initiative under its Bold. Forward. strategy, which includes advancing generative AI tools and foundation models to assist with clinical decision-making. Ad Statistics Ampronix, a Top Master Distributor for Sony Medical, provides Sales, Service & Exchanges for Sony Surgical Displays, Printers, & More. Rely on Us for Expert Support Tailored to Your Needs. Email info@ampronix.com or Call 949-273-8000 for Premier Pricing. "Our aspiration for AI is to meaningfully improve patient outcomes by detecting disease early enough to intervene," said Dr. Matthew Callstrom, medical director of strategy and leader of Mayo’s Generative Artificial Intelligence Program. "What was once a hypothetical — 'If only we had the right data' — is now becoming reality thanks to AI and advanced computing." The system will initially focus on high-resolution imaging applications, supporting Mayo’s collaboration with Berlin-based Aignostics in developing Atlas—a pathology foundation model trained on over 1.2 million histopathology whole-slide images. Jim Rogers, CEO of Mayo Clinic Digital Pathology, said the compute power is key to scaling Mayo’s clinical-grade models. “We’re transforming healthcare by quickly and safely developing innovative AI solutions that can improve patient outcomes and enable clinicians to dedicate more time to patient care,” Rogers said. Mayo Clinic Digital Pathology oversees the institution’s AI-driven pathology initiatives, which include scanning, data storage, and model deployment. The group also works with startups and external partners to scale and commercialize its AI solutions.
Aignostics Frequently Asked Questions (FAQ)
When was Aignostics founded?
Aignostics was founded in 2018.
Where is Aignostics's headquarters?
Aignostics's headquarters is located at Alt-Moabit 73/73A, Berlin.
What is Aignostics's latest funding round?
Aignostics's latest funding round is Series B.
How much did Aignostics raise?
Aignostics raised a total of $53.94M.
Who are the investors of Aignostics?
Investors of Aignostics include High-Tech Grunderfonds, Boehringer Ingelheim Venture Fund, VC Fonds Technologie, Wellington Partners, Athos and 8 more.
Who are Aignostics's competitors?
Competitors of Aignostics include Paige and 4 more.
What products does Aignostics offer?
Aignostics's products include R&D and 2 more.
Loading...
Compare Aignostics to Competitors
Aiosyn focuses on developing precision pathology software solutions for the healthcare sector. The company offers AI-powered algorithms that enhance digital pathology workflows and support clinical diagnostics, as well as tools for the identification of pathology-based biomarkers for drug development. Aiosyn primarily serves the healthcare industry, including pathology laboratories and biopharmaceutical companies. It was founded in 2021 and is based in Nijmegen, Netherlands.
Imagene AI specializes in AI-based precision oncology within the healthcare sector, focusing on cancer research and diagnostics. The company offers a SaaS platform that integrates imaging, molecular, and clinical data to support biomarker discovery, trial design, and patient identification. Imagene AI primarily serves the healthcare and oncology research sectors with its diagnostic and treatment solutions. It was founded in 2020 and is based in Miami, Florida.
BioAI focuses on advancing precision medicine through multimodal artificial intelligence within the biopharmaceutical sector. The company offers artificial intelligence (AI) driven services for biomarker discovery, drug target identification, and clinical data sourcing, aiming to enhance drug discovery and clinical development processes. BioAI primarily serves the biopharma industry, leveraging AI to improve disease diagnosis and predict patient responses to therapies. It was founded in 2020 and is based in Manchester, New Hampshire.
Ibex specializes in AI-based cancer diagnostics within the healthcare technology sector. The company offers AI-powered diagnostic solutions that assist pathologists in providing accurate and efficient cancer diagnoses. Its solutions are developed using advanced algorithms and digital workflows to detect cancer with clinical-grade accuracy. It was founded in 2016 and is based in Tel Aviv, Israel.
Nucleai focuses on spatial biology in precision medicine. The company provides artificial intelligence (AI)-powered image analysis applications to pharmaceutical companies and clinicians, enhancing drug development and supporting treatment decisions. It primarily serves the pharmaceutical industry. It was founded in 2018 and is based in Chicago, Illinois.
Deciphex specializes in digital pathology and artificial intelligence in the healthcare and drug development sectors. The company offers platforms and services that aim to improve pathology reporting efficiency and quality, using AI to assist pathologists and streamline the diagnostic process. Deciphex's solutions serve the medical and pharmaceutical industries, with an emphasis on health service delivery and drug development. It was founded in 2017 and is based in Dublin, Ireland.
Loading...